In an 88-year-old patient with a bloodstream infection caused by Achromobacter species and an estimated glomerular filtration rate of 41 mL/min, is trimethoprim‑sulfamethoxazole (Bactrim) an appropriate antibiotic choice?

Bactrim is NOT an appropriate choice for this patient with Achromobacter bacteremia and moderate renal impairment

For an 88-year-old patient with Achromobacter bacteremia and a GFR of 41 mL/min, trimethoprim-sulfamethoxazole (Bactrim) poses significant risks and should be avoided or used with extreme caution. While Achromobacter species may show in vitro susceptibility to TMP-SMX, the combination of advanced age, moderate renal impairment (Stage 3 CKD), and the severity of bloodstream infection creates a high-risk scenario for both treatment failure and drug toxicity.

Key Concerns with Bactrim in This Clinical Context

Renal Function and Drug Accumulation

With a GFR of 41 mL/min, this patient has moderate renal impairment requiring mandatory dose adjustment. Both trimethoprim and sulfamethoxazole are primarily renally excreted 1. The half-lives of both components are significantly prolonged in renal insufficiency 1, leading to drug accumulation. Recent pharmacokinetic data demonstrates that trimethoprim particularly accumulates when eGFR falls below 60 mL/min/1.73 m², while sulfamethoxazole may actually be underdosed in renal impairment 2, 3. This creates a problematic situation where you cannot achieve adequate sulfamethoxazole levels without risking trimethoprim toxicity.

Age-Related Pharmacokinetic Changes

At 88 years old, this patient has additional vulnerabilities. Geriatric patients show significantly reduced renal clearance of trimethoprim (19 mL/h/kg vs. 55 mL/h/kg in young adults) 1. The combination of advanced age and existing renal impairment compounds the risk of drug accumulation and toxicity.

Toxicity Risks in This Population

Bone marrow suppression is a major concern with TMP-SMX, particularly with prolonged use or in patients with renal impairment 1. Signs include thrombocytopenia, leukopenia, and megaloblastic anemia 1. In an 88-year-old with bacteremia, neutropenia could be catastrophic. Other serious adverse effects include hyperkalemia (trimethoprim blocks renal potassium secretion), acute kidney injury, and crystalluria 1.

Achromobacter-Specific Considerations

Recent susceptibility data shows that while TMP-SMX may have activity against Achromobacter species, meropenem remains the most reliable option 4, 5. Multiple case series document successful treatment of Achromobacter bacteremia with carbapenems 6, 5, 7. In one case series, all four Achromobacter bloodstream isolates were susceptible to both meropenem and TMP-SMX, but two patients died despite treatment 5.

The tentative CLSI breakpoints for Achromobacter and TMP-SMX have only recently been established 4, and clinical outcome data supporting TMP-SMX for serious Achromobacter infections (particularly bacteremia) remains limited compared to carbapenems.

Recommended Approach

First-Line Treatment

Meropenem should be the preferred agent for Achromobacter bacteremia in this patient 4, 5, 7. The tentative epidemiological cutoff for meropenem against Achromobacter is 0.5 µg/mL 4, and it requires dose adjustment for GFR 41 mL/min but is generally well-tolerated in elderly patients with renal impairment.

If TMP-SMX Must Be Used

If susceptibility testing confirms sensitivity and clinical circumstances absolutely require TMP-SMX:

• Dose reduction of approximately 33% is necessary for GFR 30-50 mL/min 2
• Standard dosing would be 160/800 mg (one double-strength tablet) once daily or every other day, NOT the typical twice-daily dosing
• Mandatory monitoring includes:
  • Complete blood count every 3-4 days (watch for cytopenias) 1
  • Serum creatinine and potassium every 2-3 days
  • Consider cystatin C to distinguish true AKI from creatinine secretion inhibition 8
• Duration should be minimized (10-14 days maximum for bacteremia) 9
• Have leucovorin 5-15 mg daily available if bone marrow suppression develops 1

Source Control

For any catheter-related Achromobacter bacteremia, catheter removal is essential 7. The organism can persist in biofilms, and medical therapy alone often fails 7.

Critical Pitfalls to Avoid

1. Do not use standard TMP-SMX dosing (160/800 mg twice daily) in this patient—this will lead to toxicity
2. Do not assume normal creatinine means normal renal function in an 88-year-old; reduced muscle mass can mask significant renal impairment 10
3. Do not rely on TMP-SMX as monotherapy for serious Achromobacter infections without documented susceptibility and close monitoring
4. Do not continue therapy if cytopenias develop—this requires immediate discontinuation and leucovorin rescue 1

In summary: Choose meropenem as first-line therapy. If TMP-SMX is used, reduce dose by 33-50%, monitor intensively for toxicity, and maintain a low threshold for switching to alternative therapy.